Multidrug-resistant tuberculosis (MDR-TB) is a public health challenge of growing concern. Approximately 580 000 people acquired MDR-TB in 2015, with children accounting for close to 30 000 of MDR-TB cases.

This year’s Global TB Symposium, organised by the World Health Organization (WHO) focused on the value of exploring the latest data on tuberculosis (TB) under the theme of Know Your Epidemic: Driving Change to End TB.

The Global TB Programme and the Special Programme for Research and Training in Tropical Diseases at the World Health Organization launch a global database for active TB drug safety monitoring and management (aDSM). Countries are now invited to contribute data to the global database.

WHO report warns global actions and investments to end TB epidemic are falling far short.

The new profiles seek to guide the drug/regimen development process, enabling important drug and regimen features to respond to the needs of end-users, care providers and policymakers.

Robust, rapid DNA-based test can serve as an alternative to sputum smear microscopy.

Geneva, 11 July 2016 – The first ever multi-country population-based survey investigating levels of the resistance to essential tuberculosis (TB) drugs was published last week in The Lancet Infectious Diseases. This work was led by the World Health Organization (WHO), in collaboration with National TB Programmes, National TB Reference Laboratories and Supranational Reference Laboratories.

The World Health Organization’s Global TB Program has established a Global Civil Society Task Force on TB to enhance the engagement of communities, non-governmental and other civil society organizations in the implementation of the End TB Strategy.

20 June 2016 - Adults and children with HIV who start antiretroviral therapy (ART) as early as possible reduce their risk of developing serious HIV-related infections, according to new findings published in the journal Clinical Infectious Diseases on 15 June 2016.

The World Health Organization (WHO)'s Global TB Program has released Frequently asked questions about the implementation of the new WHO recommendation on the use of the shorter MDR-TB regimen under programmatic conditions.